|
HUE051267T2
(hu)
|
2005-12-13 |
2021-03-01 |
Harvard College |
Sejttranszplantációs állványok
|
|
US11202759B2
(en)
|
2010-10-06 |
2021-12-21 |
President And Fellows Of Harvard College |
Injectable, pore-forming hydrogels for materials-based cell therapies
|
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
|
PT2838515T
(pt)
|
2012-04-16 |
2020-02-25 |
Harvard College |
Composições de sílica mesoporosa para modular respostas imunológicas
|
|
JP6257607B2
(ja)
|
2012-06-08 |
2018-01-10 |
アデュロ バイオテック，インコーポレイテッド |
癌免疫療法のための組成物および方法
|
|
MX361680B
(es)
|
2012-12-13 |
2018-12-13 |
Aduro Biotech Inc |
Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
|
|
SG10201708821RA
(en)
|
2013-04-29 |
2017-12-28 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
JP2016518140A
(ja)
|
2013-05-03 |
2016-06-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｉ型インターフェロンの環状ジヌクレオチド誘導法
|
|
ES2754269T3
(es)
|
2013-05-18 |
2020-04-16 |
Aduro Biotech Inc |
Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
US20160287623A1
(en)
*
|
2013-11-19 |
2016-10-06 |
The University Of Chicago |
Use of sting agonist as cancer treatment
|
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
|
ES2716685T3
(es)
|
2014-01-24 |
2019-06-14 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo para PD-1 y usos de las mismas
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
|
CR20160564A
(es)
|
2014-06-04 |
2017-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos como moduladores de sting
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
WO2016079899A1
(ja)
*
|
2014-11-20 |
2016-05-26 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
|
|
CN107148424B
(zh)
*
|
2014-12-16 |
2021-01-08 |
凯拉治疗股份公司 |
用于诱导细胞因子的环状二核苷酸
|
|
GB201501462D0
(en)
*
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3250250A4
(en)
*
|
2015-01-30 |
2019-05-22 |
President and Fellows of Harvard College |
PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
|
|
CA3013713C
(en)
|
2015-02-11 |
2025-09-09 |
The Johns Hopkins University |
Bacteria overexpressing the C-DI-AMP molecule and associated therapeutic methods
|
|
CA2979215A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
WO2016164705A1
(en)
|
2015-04-10 |
2016-10-13 |
Omar Abdel-Rahman Ali |
Immune cell trapping devices and methods for making and using the same
|
|
WO2016170176A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
CN108025051B
(zh)
*
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
CN106692967A
(zh)
*
|
2015-08-12 |
2017-05-24 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合PD1的抗体（Nivolumab）在制备抗肿瘤药物中的应用
|
|
MA42608A
(fr)
*
|
2015-08-13 |
2018-06-20 |
Merck Sharp & Dohme |
Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN106540255A
(zh)
*
|
2015-09-18 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
|
|
CN108430503A
(zh)
|
2015-10-28 |
2018-08-21 |
艾杜罗生物科技公司 |
用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法
|
|
CN108430515B
(zh)
|
2015-10-29 |
2021-11-12 |
诺华股份有限公司 |
包含toll-样受体激动剂的抗体缀合物
|
|
CA3006930A1
(en)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
|
US20170199961A1
(en)
|
2015-12-16 |
2017-07-13 |
Gritstone Oncology, Inc. |
Neoantigen Identification, Manufacture, and Use
|
|
WO2017106740A1
(en)
*
|
2015-12-16 |
2017-06-22 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
BR112018014150A2
(en)
|
2016-01-11 |
2018-12-11 |
Novartis Ag |
immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
|
|
KR20250049441A
(ko)
|
2016-01-11 |
2025-04-11 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
CN106544319A
(zh)
*
|
2016-01-24 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法
|
|
JP7138864B2
(ja)
|
2016-02-06 |
2022-09-20 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
免疫を再構成するための造血ニッチの再現
|
|
EP3429596B1
(en)
*
|
2016-03-18 |
2022-08-31 |
Immune Sensor, LLC |
Cyclic di-nucleotide compounds and methods of use
|
|
CN106540256A
(zh)
*
|
2016-03-27 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
|
|
ES2781474T3
(es)
|
2016-04-07 |
2020-09-02 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas
|
|
PE20181884A1
(es)
|
2016-04-07 |
2018-12-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas
|
|
EP3445761A1
(en)
|
2016-04-19 |
2019-02-27 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
US10533007B2
(en)
|
2016-04-19 |
2020-01-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
US10696985B1
(en)
|
2016-06-06 |
2020-06-30 |
Vanderbilt University |
Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
|
|
WO2018009466A1
(en)
*
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
KR102569881B1
(ko)
*
|
2016-07-06 |
2023-08-22 |
에프-스타 테라퓨틱스 인코포레이티드 |
질병 치료용 화합물, 조성물 및 방법
|
|
TW201803886A
(zh)
*
|
2016-07-06 |
2018-02-01 |
史貝羅威生物科學有限公司 |
化合物、組合物及用於治療疾病之方法
|
|
JP2019522486A
(ja)
|
2016-07-13 |
2019-08-15 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
抗原提示細胞模倣足場およびそれを作製および使用するための方法
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
CA3032505A1
(en)
|
2016-08-02 |
2018-02-08 |
President And Fellows Of Harvard College |
Biomaterials for modulating immune responses
|
|
US11725035B2
(en)
|
2016-08-09 |
2023-08-15 |
Stipe Therapeutics Aps |
Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
|
|
DK3922279T3
(da)
|
2016-08-30 |
2025-02-03 |
Dana Farber Cancer Inst Inc |
Præparater til lægemiddelafgivelse og anvendelse heraf
|
|
US11052149B2
(en)
|
2016-09-19 |
2021-07-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for inducing an immune response
|
|
US10537590B2
(en)
*
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
RS62410B1
(sr)
|
2016-10-04 |
2021-10-29 |
Merck Sharp & Dohme |
Benzo[b]tiofenska jedinjenja kao agonisti sting
|
|
WO2018065360A1
(de)
|
2016-10-07 |
2018-04-12 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
AU2017341735B2
(en)
|
2016-10-11 |
2022-01-13 |
Helmholtz Center for Infection Research |
Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
JP2018090562A
(ja)
*
|
2016-12-01 |
2018-06-14 |
武田薬品工業株式会社 |
環状ジヌクレオチド
|
|
AU2017378782A1
(en)
*
|
2016-12-20 |
2019-07-04 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
US20200113924A1
(en)
*
|
2016-12-20 |
2020-04-16 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
|
EP3573718B1
(en)
*
|
2017-01-27 |
2022-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
US11021511B2
(en)
|
2017-01-27 |
2021-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018144775A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156625A1
(en)
|
2017-02-21 |
2018-08-30 |
Board Of Regents,The University Of Texas System |
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
|
|
CN106727331B
(zh)
*
|
2017-03-13 |
2022-02-01 |
杭州星鳌生物科技有限公司 |
免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
|
|
AU2018240199A1
(en)
|
2017-03-20 |
2019-10-17 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
MX2019012233A
(es)
|
2017-04-13 |
2020-01-14 |
Aduro Biotech Holdings Europe Bv |
Anticuerpos anti-sirpa.
|
|
CA3058966A1
(en)
|
2017-04-14 |
2018-10-18 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN108853144A
(zh)
*
|
2017-05-16 |
2018-11-23 |
科济生物医药（上海）有限公司 |
Toll样受体激动剂与免疫效应细胞的联用
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN111793060B
(zh)
|
2017-07-14 |
2023-06-06 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
|
EP3658565B1
(en)
|
2017-07-28 |
2022-11-09 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
|
|
WO2019027857A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
|
|
WO2019043634A2
(en)
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
|
WO2019046498A1
(en)
*
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
JP7208225B2
(ja)
*
|
2017-08-31 |
2023-01-18 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
WO2019046511A1
(en)
|
2017-08-31 |
2019-03-07 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
|
|
MX2020002646A
(es)
|
2017-09-08 |
2020-09-25 |
Univ Leland Stanford Junior |
Inhibidores de enpp1 y su uso para el tratamiento del cancer.
|
|
US11584774B2
(en)
|
2017-09-11 |
2023-02-21 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
WO2019051489A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
CN111417630B
(zh)
|
2017-10-05 |
2023-06-06 |
葛兰素史克知识产权开发有限公司 |
干扰素基因刺激因子(sting)的调节剂
|
|
EP3692033A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
|
ES3029080T3
(en)
|
2017-10-10 |
2025-06-23 |
Seattle Project Corp |
Neoantigen identification using hotspots
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
MX2020004858A
(es)
|
2017-11-10 |
2020-10-01 |
Takeda Pharmaceuticals Co |
Compuestos moduladores de sting y metodos de elaboracion y uso.
|
|
EA038805B1
(ru)
*
|
2017-11-21 |
2021-10-21 |
Такеда Фармасьютикал Компани Лимитед |
Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
|
|
US11885815B2
(en)
|
2017-11-22 |
2024-01-30 |
Gritstone Bio, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
WO2019104353A1
(en)
*
|
2017-11-27 |
2019-05-31 |
Children's Medical Center Corporation |
Stimulator of interferon genes (sting) ligands and uses thereof
|
|
EP3724205B1
(en)
*
|
2017-12-15 |
2022-06-22 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2019125974A1
(en)
|
2017-12-20 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
US11813326B2
(en)
*
|
2018-01-04 |
2023-11-14 |
Academia Sinica |
Cell-associating immunologic adjuvants for treatment enhancement
|
|
JP2021512144A
(ja)
*
|
2018-01-26 |
2021-05-13 |
ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｌｉｆｏｒｎｉａ |
環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
|
|
JP2021512104A
(ja)
|
2018-02-02 |
2021-05-13 |
ノバルティス アーゲー |
癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
|
|
EP3749681A1
(en)
*
|
2018-02-06 |
2020-12-16 |
STipe Therapeutics ApS |
Modulation of p62 and sting activity
|
|
US12220462B1
(en)
|
2018-02-13 |
2025-02-11 |
Abionyx Pharma Sa |
Complexes for delivery of cyclic dinucleotides
|
|
WO2019175145A1
(en)
|
2018-03-12 |
2019-09-19 |
Janssen Vaccines & Prevention B.V. |
Vaccines against urinary tract infections
|
|
CN110272462B
(zh)
*
|
2018-03-15 |
2023-03-10 |
南开大学 |
制备化合物的方法
|
|
TW202003032A
(zh)
|
2018-03-23 |
2020-01-16 |
美商科迪亞克生物科學公司 |
包含ｓ ｔ ｉ ｎ ｇ 促效劑之胞外囊泡
|
|
EP3774833A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Modified cyclic dinucleotide compounds
|
|
CN111971291A
(zh)
|
2018-03-27 |
2020-11-20 |
勃林格殷格翰国际有限公司 |
用作sting激动剂的含有2-氮杂-次黄嘌呤或6h-吡唑并[1,5-d][1,2,4]三嗪-7-酮的环状二核苷酸化合物
|
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
WO2019195124A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Benzothiophenes and related compounds as sting agonists
|
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
JP7351850B2
(ja)
|
2018-04-25 |
2023-09-27 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３修飾因子
|
|
CN108310378A
(zh)
*
|
2018-04-28 |
2018-07-24 |
杭州星鳌生物科技有限公司 |
一类新型免疫联体抗肿瘤创新药物的制备及其应用
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP7335277B2
(ja)
|
2018-06-01 |
2023-08-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
膀胱がんの治療のための方法
|
|
JP2021529173A
(ja)
*
|
2018-06-20 |
2021-10-28 |
イエール ユニバーシティ |
Ｒｉｇ−ｉアゴニストおよびそれを使用した処置
|
|
EP3817820A1
(en)
|
2018-07-03 |
2021-05-12 |
IFM Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
EP3818044A1
(en)
|
2018-07-03 |
2021-05-12 |
IFM Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US12291548B2
(en)
|
2018-07-10 |
2025-05-06 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
WO2020036199A1
(en)
|
2018-08-16 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Salts of compounds and crystals thereof
|
|
KR102817037B1
(ko)
|
2018-08-16 |
2025-06-04 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
WO2020037094A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
MA53438A
(fr)
|
2018-08-24 |
2021-09-15 |
Codiak Biosciences Inc |
Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
|
|
CN118878620A
(zh)
|
2018-09-06 |
2024-11-01 |
第一三共株式会社 |
环状二核苷酸衍生物及抗体药物偶联物的制造方法
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
CN112770771A
(zh)
*
|
2018-09-17 |
2021-05-07 |
丘拉提斯股份有限公司 |
包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物
|
|
WO2020061129A1
(en)
|
2018-09-19 |
2020-03-26 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and modulation of cells in vitro and in vivo
|
|
WO2020057546A1
(zh)
*
|
2018-09-21 |
2020-03-26 |
上海迪诺医药科技有限公司 |
环状二核苷酸类似物、其药物组合物及应用
|
|
EP3873614A4
(en)
|
2018-10-29 |
2022-09-07 |
Genocea Biosciences, Inc. |
TREATMENT PROCEDURES
|
|
US11161864B2
(en)
|
2018-10-29 |
2021-11-02 |
Venenum Biodesign, LLC |
Sting agonists
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
US12508233B2
(en)
|
2018-10-30 |
2025-12-30 |
Vanderbilt University |
Graft copolymers, methods of forming graft copolymers, and methods of use thereof
|
|
JP2022509929A
(ja)
|
2018-10-31 |
2022-01-25 |
ノバルティス アーゲー |
Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
US20220033435A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
EP3891165A4
(en)
*
|
2018-12-07 |
2022-08-24 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
EP3891164A4
(en)
*
|
2018-12-07 |
2022-08-24 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
WO2020143740A1
(zh)
*
|
2019-01-10 |
2020-07-16 |
南开大学 |
环二核苷酸前药分子及其制备方法和应用
|
|
JP7373571B2
(ja)
|
2019-01-14 |
2023-11-02 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
|
|
KR102865929B1
(ko)
|
2019-01-14 |
2025-09-29 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
JP7506080B2
(ja)
|
2019-01-14 |
2024-06-25 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
CN113301962A
(zh)
|
2019-01-14 |
2021-08-24 |
先天肿瘤免疫公司 |
用于治疗癌症的杂环nlrp3调节剂
|
|
WO2020150417A2
(en)
|
2019-01-17 |
2020-07-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US10998091B2
(en)
|
2019-02-07 |
2021-05-04 |
Sandeep Patil |
Systems for monitoring compliance with a patch dosage regimen and methods of using the same
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CA3129011C
(en)
*
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3934757B1
(en)
*
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020191082A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Pharmaceuticals, Inc. |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
|
EA202192392A1
(ru)
|
2019-03-18 |
2022-02-09 |
Янссен Фармасьютикалз, Инк. |
Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
|
|
US12233356B2
(en)
|
2019-03-21 |
2025-02-25 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
US20240108747A1
(en)
|
2019-03-21 |
2024-04-04 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
|
BR112021018694A2
(pt)
|
2019-03-21 |
2021-11-30 |
Codiak Biosciences Inc |
Vesículas extracelulares para distribuição de vacina
|
|
EP3946324B1
(en)
|
2019-04-04 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
US11787833B2
(en)
|
2019-05-09 |
2023-10-17 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as sting modulators
|
|
CA3139809A1
(en)
|
2019-05-10 |
2020-11-19 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
JP2022535743A
(ja)
|
2019-05-29 |
2022-08-10 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
|
|
WO2021003445A1
(en)
|
2019-07-03 |
2021-01-07 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
CA3145889A1
(en)
|
2019-07-05 |
2021-01-14 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US12435104B2
(en)
|
2019-07-25 |
2025-10-07 |
Beigene, Ltd. |
Cyclic dinucleotides as sting agonists
|
|
KR20220056176A
(ko)
|
2019-08-02 |
2022-05-04 |
메르사나 테라퓨틱스, 인코포레이티드 |
암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
EP3785719A1
(en)
*
|
2019-08-28 |
2021-03-03 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
New use of cyclic dinucleotides
|
|
WO2021061837A1
(en)
|
2019-09-23 |
2021-04-01 |
President And Fellows Of Harvard College |
Biomaterial-based antigen free vaccine and the use thereof
|
|
EP4034081A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Extracellular vesicle compositions
|
|
US20230241089A1
(en)
|
2019-09-25 |
2023-08-03 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
EP4034276A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Methods of producing extracellular vesicles
|
|
JP2022551420A
(ja)
|
2019-09-25 |
2022-12-09 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
|
|
IL291821A
(en)
|
2019-10-02 |
2022-06-01 |
Janssen Vaccines & Prevention Bv |
Staphylococcus peptides and methods of use
|
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
EP4087842A1
(en)
|
2020-01-10 |
2022-11-16 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
JP7485771B2
(ja)
|
2020-01-16 |
2024-05-16 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
ＦｉｍＨ変異体、その組成物、及びその使用
|
|
IL295759A
(en)
|
2020-02-28 |
2022-10-01 |
Tallac Therapeutics Inc |
Transglutaminase mediated coupling
|
|
PH12022551961A1
(en)
|
2020-03-06 |
2023-10-09 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugate including novel cyclic dinucleotide derivative
|
|
US20230114434A1
(en)
|
2020-03-13 |
2023-04-13 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
AU2021236763A1
(en)
|
2020-03-20 |
2022-10-06 |
Lonza Sales Ag |
Extracellular vesicles for therapy
|
|
AU2021248635B2
(en)
|
2020-04-02 |
2025-10-23 |
Mersana Therapeutics, Inc. |
Antibody drug conjugates comprising STING agonists
|
|
EP4134098A4
(en)
|
2020-04-10 |
2024-05-15 |
ONO Pharmaceutical Co., Ltd. |
Method of cancer therapy
|
|
US11857618B2
(en)
|
2020-04-17 |
2024-01-02 |
Emory University |
Boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
|
|
CA3178260A1
(en)
|
2020-05-13 |
2021-11-18 |
Massachusetts Institute Of Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN116056765A
(zh)
|
2020-08-07 |
2023-05-02 |
坦伯公司 |
反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
|
|
AU2021338014A1
(en)
|
2020-09-02 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Novel endo-β-N-acetylglucosaminidase
|
|
BR112023004271A2
(pt)
|
2020-09-08 |
2023-04-04 |
Univ Texas |
Composições de ativação de sting polivalentes e usos das mesmas
|
|
PH12023550020A1
(en)
|
2020-09-17 |
2024-03-11 |
Janssen Pharmaceuticals Inc |
Multivalent vaccine compositions and uses thereof
|
|
EP4216993A2
(en)
|
2020-09-23 |
2023-08-02 |
Codiak BioSciences, Inc. |
Methods of producing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
EP4217087A2
(en)
|
2020-09-23 |
2023-08-02 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
WO2022079175A1
(en)
|
2020-10-14 |
2022-04-21 |
Boehringer Ingelheim International Gmbh |
Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
|
|
EP3984535A1
(en)
|
2020-10-16 |
2022-04-20 |
Albert-Ludwigs-Universität Freiburg |
Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
|
|
CN115160392B
(zh)
*
|
2020-10-20 |
2026-01-30 |
泰励生物科技（上海）有限公司 |
多功能环二核苷酸及其用途
|
|
TWI901793B
(zh)
|
2020-10-20 |
2025-10-21 |
大陸商泰勵生物科技（上海）有限公司 |
多功能環二核苷酸及其用途
|
|
KR20230141754A
(ko)
|
2020-10-30 |
2023-10-10 |
아박타 라이프 사이언시스 리미티드 |
Fap-활성화 혈청 반감기 연장된 치료 접합체
|
|
EP4240488A1
(en)
|
2020-11-09 |
2023-09-13 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
KR20230121800A
(ko)
|
2020-12-17 |
2023-08-21 |
트러스티즈 오브 터프츠 칼리지 |
Fap-활성화된 래디오테라노스틱스, 및 이와 관련된용도
|
|
EP4274824A1
(en)
|
2021-01-08 |
2023-11-15 |
IFM Due, Inc. |
Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
|
|
US11725028B2
(en)
|
2021-01-12 |
2023-08-15 |
Janssen Pharmaceuticals, Inc. |
FimH mutants, compositions therewith and use thereof
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
CN117222427A
(zh)
|
2021-04-01 |
2023-12-12 |
杨森制药公司 |
大肠杆菌o18生物缀合物的生产
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
JP2024514707A
(ja)
|
2021-04-20 |
2024-04-02 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
US20220313724A1
(en)
*
|
2021-05-17 |
2022-10-06 |
Highlight Therapeutics, S.L. |
Compositions for intratumoral administration and related methods
|
|
EP4359544A4
(en)
*
|
2021-06-24 |
2025-08-13 |
Univ Miami |
STING-DEPENDENT ADJUVANTS
|
|
TW202317087A
(zh)
|
2021-08-10 |
2023-05-01 |
美商Ｉｆｍ Ｄｕｅ有限公司 |
用於治療與sting活性相關病況之化合物及組合物
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
EP4413038A1
(en)
|
2021-10-07 |
2024-08-14 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
|
CN114106140A
(zh)
*
|
2021-11-23 |
2022-03-01 |
哈尔滨医科大学附属肿瘤医院 |
一种表达特定sting异构体、细胞系、制备方法、用途
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
JPWO2023167238A1
(da)
|
2022-03-02 |
2023-09-07 |
|
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
KR20250054799A
(ko)
|
2022-08-29 |
2025-04-23 |
다이이찌 산쿄 가부시키가이샤 |
변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
|
|
EP4687796A1
(en)
|
2023-04-05 |
2026-02-11 |
Massachusetts Institute of Technology |
Hybrid polymeric systems and methods of use thereof
|
|
WO2026027944A1
(en)
|
2024-07-30 |
2026-02-05 |
Sairopa B.V. |
Anti-sirp alpha antibody formulations and uses thereof
|